At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 target
Drug / intervention
autologous peripheral blood stem cell transplantation, ex vivo amplifiedprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Clinical Trial of Injection of ex Vivo Amplified G-CSF Mobilised Autologous Peripheral Blood Stem Cell Transplantation in Adult Patients With Multiple Myeloma in First Response
In Brief
A Phase 2 clinical trial evaluating autologous peripheral blood stem cell transplantation, ex vivo amplified for Multiple Myeloma. Completed, enrolled 13 participants across 1 site.
Detailed Summary
Hematopoietic reconstitution defined by a neutrophils number \> 500/mm3 at day 7 after injection of ex vivo amplified graft and by a platelets number \> 20000/mm3, at day 15 after the injection of ex vivo amplified graft, without transfusion.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesFrance
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2007
Enrollment StartAug 2007
Primary CompletionSep 2008
Study CompletionAug 2009
TodayJul 2026
First PostedApr 18, 2007
Enrollment StartAug 1, 2007
Primary CompletionSep 1, 2008
Study CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 19.2 years ago
Interventions
autologous peripheral blood stem cell transplantation, ex vivo amplifiedprocedure
autologous peripheral blood stem cell transplantation, ex vivo amplified